Literature DB >> 28154904

Less is more: reconsidering the need for regular use of diagnostic whole body radioiodine scintigraphy in the follow-up of differentiated thyroid cancer.

Christian Pirich1, Gregor Schweighofer-Zwink2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28154904     DOI： 10.1007/s00259-017-3632-5

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  19 in total

1.  [Procedure guideline for iodine-131 whole-body scintigraphy for differentiated thyroid cancer (version 3)].

Authors:  M Dietlein; J Dressler; W Eschner; F Grünwald; M Lassmann; B Leisner; M Luster; C Reiners; H Schicha; O Schober
Journal:  Nuklearmedizin       Date:  2007       Impact factor: 1.379

Review 2.  The changing incidence of thyroid cancer.

Authors:  Cari M Kitahara; Julie A Sosa
Journal:  Nat Rev Endocrinol       Date:  2016-07-15       Impact factor: 43.330

Review 3.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

4.  Evaluation of 131I scintigraphy and stimulated thyroglobulin levels in the follow up of patients with DTC: a retrospective analysis of 1420 patients.

Authors:  Jose Manuel Gonzalez Carvalho; Dennis Görlich; Otmar Schober; Christian Wenning; Burkhard Riemann; Frederik Anton Verburg; Alexis Vrachimis
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-12-01       Impact factor: 9.236

5.  Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment.

Authors:  F Pacini; M Capezzone; R Elisei; C Ceccarelli; D Taddei; A Pinchera
Journal:  J Clin Endocrinol Metab       Date:  2002-04       Impact factor: 5.958

Review 6.  German Association of Endocrine Surgeons practice guideline for the surgical management of malignant thyroid tumors.

Authors:  Henning Dralle; Thomas J Musholt; Jochen Schabram; Thomas Steinmüller; Andreja Frilling; Dietmar Simon; Peter E Goretzki; Bruno Niederle; Christian Scheuba; Thomas Clerici; Michael Hermann; Jochen Kußmann; Kerstin Lorenz; Christoph Nies; Peter Schabram; Arnold Trupka; Andreas Zielke; Wolfram Karges; Markus Luster; Kurt W Schmid; Dirk Vordermark; Hans-Joachim Schmoll; Reinhard Mühlenberg; Otmar Schober; Harald Rimmele; Andreas Machens
Journal:  Langenbecks Arch Surg       Date:  2013-03-03       Impact factor: 3.445

7.  Guidelines for radioiodine therapy of differentiated thyroid cancer.

Authors:  M Luster; S E Clarke; M Dietlein; M Lassmann; P Lind; W J G Oyen; J Tennvall; E Bombardieri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-10       Impact factor: 9.236

8.  Initial [18F]FDG PET/CT in high-risk DTC patients. A three-year follow-up.

Authors:  Marcus Ruhlmann; Ina Binse; Andreas Bockisch; Sandra J Rosenbaum-Krumme
Journal:  Nuklearmedizin       Date:  2016-02-02       Impact factor: 1.379

9.  Posttherapeutic (131)I SPECT-CT offers high diagnostic accuracy when the findings on conventional planar imaging are inconclusive and allows a tailored patient treatment regimen.

Authors:  S Kohlfuerst; I Igerc; M Lobnig; H J Gallowitsch; I Gomez-Segovia; S Matschnig; J Mayr; P Mikosch; M Beheshti; P Lind
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-01-24       Impact factor: 9.236

10.  Mortality Risk Stratification by Combining BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Cancer: Genetic Duet of BRAF and TERT Promoter Mutations in Thyroid Cancer Mortality.

Authors:  Rengyun Liu; Justin Bishop; Guangwu Zhu; Tao Zhang; Paul W Ladenson; Mingzhao Xing
Journal:  JAMA Oncol       Date:  2017-02-01       Impact factor: 31.777
View more
  3 in total

1.  Recombinant human thyrotropin versus thyroid hormone withdrawal in differentiated thyroid carcinoma follow-up: a single center experience.

Authors:  M Sahin; B I Aydoğan; E Özkan; R Emral; S Güllü; M F Erdogan; D Çorapçıoğlu
Journal:  Acta Endocrinol (Buchar)       Date:  2021 Jul-Sep       Impact factor: 0.877

Review 2.  Molecular Imaging and Theragnostics of Thyroid Cancers.

Authors:  Luca Giovanella; Desiree' Deandreis; Alexis Vrachimis; Alfredo Campenni; Petra Petranovic Ovcaricek
Journal:  Cancers (Basel)       Date:  2022-03-01       Impact factor: 6.639

3.  Impact of a non-return-to-work prognostic model (WORRK) on allocation to rehabilitation clinical pathways: A single centre parallel group randomised trial.

Authors:  Chantal Plomb-Holmes; Roger Hilfiker; Bertrand Leger; François Luthi
Journal:  PLoS One       Date:  2018-08-02       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.